Can nasal sprays bring hope to Covid-19?After the artificial solution test was stopped, the scientists “surprised” that they stopped replicating the virus in 96% of the infected ferrets
- Treat ferrets before being exposed to coronavirus
- The spray was originally developed to help prevent the common cold and flu
- Human spray trials may start within the next four months
Studies have shown that weekly nasal sprays can prevent Covid-19.
Ferrets receive two doses of the solution daily-containing artificial molecules designed to boost the immune system Before they were exposed to the coronavirus.
The results showed that it reduced the replication of the virus in the nose and throat by 96%, thereby reducing the risk of infection and reducing the chance of transmission.
The man-made compound is called INNA-051 and will enter human trials in the next four months.
It was originally developed to help prevent the common cold and flu, but since it has not been convincingly proven to be effective, it has not yet been rubber stamped.
Previous studies have shown that it “accelerated” the antiviral response in the throat cells of healthy volunteers and volunteers with asthma, and provided “long-term protection” for rhinovirus, which causes human runny nose.
If approved, the therapy could provide more defenses for people at higher risk of Covid-19, including the elderly and people with basic health conditions.
The treatment was first tested in ferrets, and the results showed that it can enhance the immunity of ferrets and make them more capable of preventing coronavirus
What is the revision and is it effective against the coronavirus?
Remdesivir was developed by Gilead Sciences to treat Ebola virus, a fatal hemorrhagic fever that appeared in West Africa in 2014.
Like COVID-19, the Ebola virus is also caused by a virus. Scientists are now testing remdesivir to treat coronavirus patients, but it is too early to know whether this drug works.
Remdesivir achieved encouraging results earlier this year, showing that it has the potential to prevent and treat MERS (another coronavirus) in macaques.
The drug seems to help prevent the replication of viruses like coronavirus and Ebola.
It is unclear how the drug accomplishes this feat, but it seems to prevent the virus’s genetic material RNA from replicating itself.
This prevents the virus from spreading further in the patient’s body.
Researchers at the National Institutes of Health in charge of macaque research suggested that this new type of coronavirus be used in human trials.
Scientists have been listening, and human trials of remdesivir were first started in Nebraska.
According to a Stat News report, researchers who tried the drug at the University of Chicago recently reported that most of the 125 COVID-19 patients they teased with the drug have been discharged from the hospital.
Two patients died during the trial.
A paper detailing the INNA-051 trial has been published on the research website bioRxiv, although it has yet to be peer reviewed.
The spray was developed by the Australian company Ena Respiratory, which started avant-garde treatments before the pandemic.
It contains molecules designed to trigger TLR2 and TLR6 receptors on the epithelial cells of the mucosa around the throat and nose, attracting swarms of white blood cells to the area and boosting immunity.
The spray test on ferrets was led by Professor Miles Carroll, Deputy Director and Head of Research at Porton Down, Department of Public Health.
Dr Christophe Demaison, managing director of Melbourne-based Ena Respiratory, said: “We were surprised by the effectiveness of the treatment.
“Through our treatment to enhance the natural immune response of ferrets, we have seen the rapid elimination of this virus.”
He added: “If humans respond in a similar way, the benefits of treatment are twofold.
Individuals exposed to the virus are likely to quickly eliminate the virus and use treatment to ensure that the disease does not develop beyond mild symptoms.
“This is particularly relevant to disadvantaged groups in the community.
“In addition, the rapidity of this response means that infected individuals are unlikely to continue to spread, which means that community transmission will stop quickly.”
The company said that if human trials prove to be successful and there are sufficient funds, this therapy may be quickly mass-produced.
Professor Roberto Solari, a respiratory expert consultant for Ena’s respiratory system and a visiting professor at Imperial College London, said: “This is a major development because the world is racing to find a solution to stop Covid-19. People at high risk of spreading and infecting.
“The most exciting thing is the ability of INNA-051 to significantly reduce the level of the virus in the nose and throat, which makes people hope that this therapy can reduce the number of infected people, especially those with or without symptoms, from contracting Covid- 19 capacity. Contagious. “
The company had previously received as much as 6.4 million pounds ($8.25 million) in funding and called for further financial support in the trial.
The treatment is designed to enhance protection against all respiratory diseases, not just the coronavirus.
The test was performed on 24 female ferrets who received different doses of spray and were sedated during the administration.
This is a challenging experiment, which means that after treatment with a possible protective drug, the animal is exposed to an infectious agent to see if it works.